NEUROPTICS, INC.

NeurOptics is a worldwide leader in pupillometry technology for critical care, neurology, neurosurgery, emergency medicine, and applied research. The company develops and markets the NPi-300 Pupillometer, a handheld device that provides objective, quantitative assessment of pupil size and reactivity independent of examiner variability. The NPi-300 is adopted in over 1,000 U.S. hospitals and represented in more than 50 countries globally. The device measures pupillary responses and constriction velocity, enabling clinicians to detect subtle changes in pupillary response that may indicate increased intracranial pressure, neurological decline, or brain injury—particularly valuable in sedated or comatose patients where subjective penlight examination is unreliable. NeurOptics also provides pupillometry instrumentation for applied research applications, supporting both human and animal research across various clinical and research settings. The company emphasizes device integration with electronic medical records (EMR) to streamline clinical workflows and enable trend analysis of pupillary data as a vital sign. The NPi-300 is used extensively in neurocritical care units, stroke services, trauma centers, and cardiac arrest care settings. Clinical evidence supports the device in management of traumatic brain injury, cardiac arrest, malignant cerebral edema, and assessment for brain death determination.